Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy

Györgyi Muzes, Ferenc Sipos, Judit Csomor, Lídia Sréter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We present and discuss the case of a HIV-negative female finally diagnosed upon histopathologic and molecular biologic evaluations with human herpesvirus 8 (HHV8)-positive multicentric Castleman's disease (MCD) of plasma cell type, but with no detectable HHV8-DNA in peripheral blood. She failed to respond to combination immunosuppressive therapeutic trials of corticosteroids and azathioprine, and neither an immunochemotherapy of rituximab-CVP (R-CVP) induced disease resolution. However, monoclonal anti-IL-6R antibody (tocilizumab) immunotherapy resulted in beneficial disease stabilization. A control lymph node biopsy indicated mild polyclonal plasmacytosis, and a negative HHV8 determination. The patient is still receiving tocilizumab. This case emphasizes the individual nature of MCD requiering more personalized disease management.

Original languageEnglish
Pages (from-to)668-674
Number of pages7
JournalAPMIS
Volume121
Issue number7
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Human herpesvirus 8
  • Interleukin-6
  • Multicentric Castleman's disease
  • Rituximab
  • Tocilizumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Successful Tocilizumab Treatment In A Patient With Human Herpesvirus 8-Positive And Human Immunodeficiency Virus-Negative Multicentric Castleman's Disease Of Plasma Cell Type Nonresponsive To Rituximab-CVP Therapy'. Together they form a unique fingerprint.

  • Cite this